The Europe Skin Cancer Diagnostics Market is projected to witness market growth of 5.0% CAGR during the forecast period (2024-2031).
The Germany market dominated the Europe Skin Cancer Diagnostics Market by Country in 2023, and is forecast to continue being a dominant market till 2031; thereby, achieving a market value of $895.1 million by 2031. The UK market is exhibiting a CAGR of 4.1% during (2024 - 2031). Additionally, The France market would exhibit a CAGR of 5.9% during (2024 - 2031).
The rising incidence of skin cancer is a central driver of the market. The direct DNA damage that UV radiation causes in skin cells is a well-established risk factor for skin cancer, which can result in malignant transformations. Demographic trends also significantly influence the growing demand for skin cancer diagnostics.
Additionally, Consequently, the aging population is more susceptible to both melanoma and non-melanoma skin cancers, necessitating more frequent and sophisticated diagnostic interventions.
The risk of developing skin cancer demonstrably increases with age. Cumulative sun exposure throughout a lifetime plays a major role. As the European population ages, a greater number of individuals are inherently more susceptible to skin cancer. The demand for skin cancer diagnostics in the United Kingdom is increasing significantly due to an aging population. Non-melanoma skin cancer incidence rates are projected to rise by 14% from 2023-2025 to 2038-2040, reaching 310 cases per 100,000 people annually by 2038-2040.
The Germany market dominated the Europe Skin Cancer Diagnostics Market by Country in 2023, and is forecast to continue being a dominant market till 2031; thereby, achieving a market value of $895.1 million by 2031. The UK market is exhibiting a CAGR of 4.1% during (2024 - 2031). Additionally, The France market would exhibit a CAGR of 5.9% during (2024 - 2031).
The rising incidence of skin cancer is a central driver of the market. The direct DNA damage that UV radiation causes in skin cells is a well-established risk factor for skin cancer, which can result in malignant transformations. Demographic trends also significantly influence the growing demand for skin cancer diagnostics.
Additionally, Consequently, the aging population is more susceptible to both melanoma and non-melanoma skin cancers, necessitating more frequent and sophisticated diagnostic interventions.
The risk of developing skin cancer demonstrably increases with age. Cumulative sun exposure throughout a lifetime plays a major role. As the European population ages, a greater number of individuals are inherently more susceptible to skin cancer. The demand for skin cancer diagnostics in the United Kingdom is increasing significantly due to an aging population. Non-melanoma skin cancer incidence rates are projected to rise by 14% from 2023-2025 to 2038-2040, reaching 310 cases per 100,000 people annually by 2038-2040.
List of Key Companies Profiled
- Castle Biosciences, Inc.
- Bausch Health Companies, Inc. (DermTech, Inc.)
- Canfield Scientific, Inc.
- DermaSensor, Inc.
- F.Hoffmann-La Roche Ltd.
- NeoGenomics, Inc.
- Quest Diagnostics Incorporated.
- Digital Diagnostics, Inc. (3Derm Systems, Inc.)
- FotoFinder Systems GmbH
- Veriskin Inc
Market Report Segmentation
By Type- Non-Melanoma
- Melanoma
- Skin Biopsy
- Imaging Tests
- Dermatoscopy
- Lymph Node Biopsy
- Others
- Hospital & Clinics
- Laboratories
- Others
- Germany
- UK
- France
- Russia
- Spain
- Italy
- Rest of Europe
Table of Contents
Chapter 1. Market Scope & Methodology
Chapter 2. Market at a Glance
Chapter 3. Market Overview
Chapter 4. Europe Skin Cancer Diagnostics Market by Type
Chapter 5. Europe Skin Cancer Diagnostics Market by Test Type
Chapter 6. Europe Skin Cancer Diagnostics Market by End-use
Chapter 7. Europe Skin Cancer Diagnostics Market by Country
Chapter 8. Company Profiles
Companies Mentioned
- Castle Biosciences, Inc.
- Bausch Health Companies, Inc. (DermTech, Inc.)
- Canfield Scientific, Inc.
- DermaSensor, Inc.
- F. Hoffmann-La Roche Ltd.
- NeoGenomics, Inc.
- Quest Diagnostics Incorporated.
- Digital Diagnostics, Inc. (3Derm Systems, Inc.)
- FotoFinder Systems GmbH
- Veriskin Inc
Methodology
LOADING...
